Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2011

View Archived Issues

Phase I/II trial of mesenchymal stem cells for Crohn's disease-associated fistulas advances

Dopaminergic gene variations influence response to antipsychotics

New Toll-like receptor 7 agonist PF-4171455 selected for investigation for hepatitis C

Preclinical and clinical phase I data presented on THR-18 for stroke

Blood biomarkers can differentiate stroke and stroke-mimicking conditions

AstraZeneca's AZ-876 inhibits atherosclerosis and shows no inflammatory effects in vivo

Abbott updates highlights for fourth quarter of 2010

Threshold Pharma and FDA agree on SPA for phase III TH-302 trial in soft tissue sarcoma

Sanofi-aventis withdraws Anzemet for chemotherapy-induced nausea and vomiting

Pantarhei Bioscience seeks to acquire women's health activities from Organon

FDA approves aripiprazole for bipolar I disorder as an adjunct to mood stabilizers

Inspire Pharma discontinues development of denufosol for cystic fibrosis

DPZ and Ascenion sign license agreement for recombinant VP1-containing VLP

Acadra shows promise in phase I/IIa trial in chronic lymphocytic leukemia

Phase II trial of PXL-01 for prevention of postsurgical adhesions is extended to Germany

Novartis claims new inhibitors of serine/threonine-protein kinase D1

Dosing complete in phase I trial of HuCNS-SC in pediatric Pelizaeus-Merzbacher disease

Santhera regains rights to fipamezole from Biovail

Cytochroma begins phase IIb trial of CTAP-101 for vitamin D insufficiency in chronic kidney disease

Astellas' Protopic approved in Canada for prevention of eczema flares

Chimerix receives BARDA contract to develop CMX-001 for smallpox

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...